He is a neurologist by training and has over 20 years of experience in the field of neurodegenerative diseases. His primary research focus is on the molecular pathogenesis of neurodegenerative diseases, with a particular emphasis on protein aggregation and the development of therapies aiming at disease modification, including the compound anle138b. He is the principal investigator in international cohort studies such as the Dominantly Inherited Alzheimer’s Network (DIAN) and the Genetic Frontotemporal dementia Initiative (GENFI). His work has contributed to the definition of natural history, environmental factors, symptomatic treatment and disease modification of neurodegenerative diseases.